Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

TLPH

Talphera Inc.

Last Close
Jun 18 • 04:00PM ET
0.7811
Dollar change
-0.2119
Percentage change
-21.34 		%
Held by: VTI VXF Scroll to Statements
Index- P/E- EPS (ttm)-0.89 Insider Own1.17% Shs Outstand16.95M Perf Week-19.93%
Market Cap13.27M Forward P/E- EPS next Y-0.84 Insider Trans5.30% Shs Float16.79M Perf Month-27.68%
Income-14.20M PEG- EPS next Q-0.21 Inst Own31.29% Short Float1.00% Perf Quarter-31.48%
Sales0.65M P/S20.42 EPS this Y37.47% Inst Trans2.83% Short Ratio2.62 Perf Half Y-3.45%
Book/sh0.96 P/B0.81 EPS next Y-3.72% ROA-51.96% Short Interest0.17M Perf Year-33.81%
Cash/sh1.09 P/C0.71 EPS next 5Y- ROE-93.57% 52W Range0.43 - 1.61 Perf YTD6.27%
Dividend Est.- P/FCF- EPS past 5Y39.67% ROI-62.69% 52W High-51.48% Beta0.35
Dividend TTM- Quick Ratio5.97 Sales past 5Y-0.99% Gross Margin-22.73% 52W Low83.79% ATR (14)0.08
Dividend Ex-Date- Current Ratio5.97 EPS Y/Y TTM-112.83% Oper. Margin-2426.73% RSI (14)30.12 Volatility13.75% 7.82%
Employees15 Debt/Eq0.39 Sales Y/Y TTM-51.02% Profit Margin-2181.11% Recom1.00 Target Price4.42
Option/ShortYes / Yes LT Debt/Eq0.39 EPS Q/Q78.63% Payout- Rel Volume5.86 Prev Close0.99
Sales Surprise- EPS Surprise36.00% Sales Q/Q- EarningsMay 14 AMC Avg Volume64.14K Price0.78
SMA20-23.21% SMA50-24.76% SMA200-12.80% Trades Volume375,681 Change-21.34%
Date Action Analyst Rating Change Price Target Change
Jul-20-20Downgrade Credit Suisse Neutral → Underperform
Nov-11-19Downgrade Credit Suisse Outperform → Neutral $7 → $2
Aug-05-19Resumed Credit Suisse Outperform
Jul-10-19Resumed Credit Suisse Outperform
Apr-24-19Resumed B. Riley FBR Buy $6.50
Feb-15-19Initiated Credit Suisse Outperform $7
Oct-23-18Initiated B. Riley FBR Buy $9
Oct-13-17Reiterated RBC Capital Mkts Outperform $6 → $5
Oct-13-17Downgrade Jefferies Buy → Hold
Jul-14-17Resumed Jefferies Buy $7
Show Previous Ratings
May-20-24 05:25PM
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
(PR Newswire)
May-16-24 05:45PM
Talphera to Participate at A.G.P. Virtual Healthcare Conference
(PR Newswire) -5.35% -6.09%
May-14-24 08:56PM
TLPH Stock Earnings: Talphera Beats EPS for Q1 2024
(InvestorPlace) +19.12%
04:05PM
Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update
(PR Newswire)
May-02-24 04:15PM
Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024
(PR Newswire)
Mar-06-24 09:53PM
TLPH Stock Earnings: Talphera Misses EPS, Beats Revenue for Q4 2023
(InvestorPlace) -10.63%
04:05PM
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
(PR Newswire)
Mar-01-24 07:30AM
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
(PR Newswire)
Feb-26-24 04:15PM
Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024
(PR Newswire)
Jan-18-24 08:30AM
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
(PR Newswire) +26.01%
Jan-09-24 09:05AM
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
(PR Newswire) +7.50%
Dec-12-23 08:30AM
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
(PR Newswire) -9.01%
Nov-09-23 11:06AM
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript
(Insider Monkey) -11.34%
Nov-08-23 05:22PM
AcelRx Pharmaceuticals: Q3 Earnings Snapshot
(Associated Press Finance)
04:05PM
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
(PR Newswire)
Nov-07-23 04:05PM
AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad Clinical Study
(PR Newswire)
Oct-26-23 04:30PM
AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
(PR Newswire)
Oct-03-23 08:30AM
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
(PR Newswire)
Sep-12-23 01:02PM
Insider Buying: CEO Vincent Angotti Acquires 10,000 Shares of AcelRx Pharmaceuticals Inc
(GuruFocus.com) +12.80%
Sep-06-23 08:30AM
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
(PR Newswire)
Aug-22-23 05:30PM
What Makes AcelRx Pharmaceuticals (ACRX) a New Buy Stock
(Zacks)
Aug-13-23 05:33AM
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q2 2023 Earnings Call Transcript
(Insider Monkey)
Aug-11-23 06:07AM
Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents)
Aug-10-23 05:30PM
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Tops Revenue Estimates
(Zacks) -5.46%
04:20PM
AcelRx Pharmaceuticals: Q2 Earnings Snapshot
(Associated Press Finance)
04:05PM
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
(PR Newswire)
Jul-27-23 04:05PM
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023
(PR Newswire)
Jul-21-23 08:00AM
AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules
(PR Newswire)
Jul-18-23 08:00AM
AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
(PR Newswire)
May-10-23 06:25PM
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
(Zacks) +10.88%
05:18PM
AcelRx Pharmaceuticals: Q1 Earnings Snapshot
(AP Finance)
04:05PM
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
(PR Newswire)
May-04-23 10:00AM
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline
(Zacks)
May-03-23 10:00AM
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
(Zacks)
Apr-27-23 04:05PM
AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023
(PR Newswire)
Apr-05-23 08:30AM
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
(PR Newswire)
Apr-04-23 12:30PM
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call Transcript
(Insider Monkey)
Mar-30-23 06:15PM
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
(Zacks) -6.00%
04:05PM
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
(PR Newswire)
Mar-29-23 10:13AM
12 Cheap Healthcare Stocks to Buy in 2023
(Insider Monkey)
Mar-21-23 04:05PM
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
(PR Newswire) +18.10% +5.68%
Mar-14-23 08:30AM
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
(PR Newswire) -21.05%
Mar-01-23 08:30AM
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures
(PR Newswire) -7.04%
Dec-29-22 06:02AM
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2022 Earnings Call Transcript
(Insider Monkey) +7.58%
Dec-27-22 08:30AM
AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
(PR Newswire)
Dec-19-22 08:17AM
10 Cheapest Stocks With Biggest Upside
(Insider Monkey) -7.95%
Dec-08-22 08:30AM
AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine
(PR Newswire)
Nov-17-22 05:17AM
AcelRx Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
(Simply Wall St.)
Nov-14-22 05:15PM
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
(Zacks) +17.96%
04:01PM
AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
(PR Newswire)
Nov-03-22 08:30AM
AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022
(PR Newswire)
Oct-31-22 08:30AM
AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022
(PR Newswire)
Oct-27-22 08:30AM
AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant
(PR Newswire) -12.47%
Oct-26-22 08:30AM
AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY® Annual Meeting 2022
(PR Newswire) -12.81%
Oct-25-22 04:42PM
AcelRx Pharmaceuticals Announces Reverse Stock Split
(PR Newswire)
08:30AM
AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences
(PR Newswire)
Sep-06-22 04:30PM
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
(PR Newswire) -7.32% +5.74%
Aug-25-22 08:30AM
AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
(PR Newswire)
Aug-11-22 05:35PM
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates
(Zacks) +33.02% -13.63%
04:01PM
AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
(PR Newswire)
08:30AM
AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022
(PR Newswire)
Aug-10-22 08:30AM
AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
(PR Newswire)
Jul-28-22 04:50PM
AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022
(PR Newswire)
Jul-08-22 06:28AM
AcelRx Pharmaceuticals (NASDAQ:ACRX) shareholders are up 44% this past week, but still in the red over the last three years
(Simply Wall St.) -13.71%
May-20-22 12:49PM
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference
(PR Newswire) -11.83%
May-19-22 11:56AM
Why AcelRx Pharma Shares Are Trading Higher Today?
(Benzinga) +27.63%
08:30AM
AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®
(PR Newswire)
May-16-22 08:45AM
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates
(Zacks)
07:30AM
AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
(PR Newswire)
May-12-22 05:35PM
Acutus Medical, Inc. (AFIB) Reports Q1 Loss, Tops Revenue Estimates
(Zacks) +17.66%
May-10-22 05:35PM
Organogenesis (ORGO) Q1 Earnings Lag Estimates
(Zacks) -10.10%
08:30AM
AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia
(PR Newswire)
May-09-22 07:30PM
AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022
(PR Newswire) -13.47%
Apr-27-22 08:00AM
AcelRx Hosting Key Opinion Leader Webinar on Niyad Nafamostat Program
(GlobeNewswire)
Apr-25-22 08:30AM
Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022
(PR Newswire)
Apr-21-22 08:30AM
AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022
(PR Newswire) -8.00%
Mar-31-22 04:10PM
AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures
(PR Newswire)
Mar-29-22 01:08PM
AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit
(PR Newswire) -6.87%
Mar-10-22 05:15PM
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Misses Revenue Estimates
(Zacks) -20.63%
04:01PM
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
(PR Newswire)
Mar-03-22 04:05PM
AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022
(PR Newswire) -7.14%
Feb-01-22 08:30AM
AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures
(PR Newswire)
Jan-31-22 04:24AM
When Will AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Breakeven?
(Simply Wall St.) +11.77%
Jan-27-22 01:38PM
Edmonds Duncan Registered Investment Advisors, LLC Buys VanEck Vectors Semiconductor ETF, ...
(GuruFocus.com) -8.64%
08:30AM
AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures
(PR Newswire)
Jan-12-22 08:30AM
AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet in Joint Replacement Surgery
(PR Newswire) -5.53%
Jan-10-22 08:30AM
AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics
(PR Newswire)
Dec-23-21 08:05AM
Femasys Inc. to Participate in Upcoming January Investor Conferences
(GlobeNewswire)
Dec-15-21 08:30AM
AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surgery
(PR Newswire)
Dec-01-21 07:12PM
Penny Stocks to Buy Using Technical Analysis for December 2021
(Investopedia)
Nov-23-21 05:09PM
AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors
(PR Newswire) -5.22%
Nov-15-21 06:45AM
AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering
(PR Newswire) -6.08%
06:00AM
AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results
(PR Newswire)
Nov-10-21 08:30AM
AcelRx to Host Third Quarter 2021 Financial Results Call and Webcast on November 15, 2021
(PR Newswire)
Nov-02-21 06:22AM
Investors in AcelRx Pharmaceuticals (NASDAQ:ACRX) have unfortunately lost 80% over the last three years
(Simply Wall St.)
Oct-28-21 03:06PM
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
(Zacks)
Oct-21-21 09:32PM
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Provention Bio, Danimer Scientific, AcelRX, and Piedmont Lithium on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
(GlobeNewswire) -5.18%
Oct-04-21 07:30AM
Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors
(GlobeNewswire)
Sep-10-21 03:19PM
AcelRx Pharmaceuticals to Participate in Two September Investor Conferences
(PR Newswire)
Aug-30-21 05:10PM
Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG)
(ACCESSWIRE)
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Angotti Vincent J.CHIEF EXECUTIVE OFFICERJun 14 '24Buy1.081,3041,404180,806Jun 14 05:19 PM
Angotti Vincent J.CHIEF EXECUTIVE OFFICERJun 13 '24Buy0.974,5704,438179,502Jun 14 05:19 PM
Angotti Vincent J.CHIEF EXECUTIVE OFFICERJun 12 '24Buy0.974,1264,013174,932Jun 14 05:19 PM
Angotti Vincent J.Chief Executive OfficerDec 13 '23Buy0.7310,0007,268101,805Dec 14 08:11 AM
Angotti Vincent J.Chief Executive OfficerSep 11 '23Buy0.8010,0007,95091,805Sep 11 07:13 PM
Palmer Pamela PChief Medical OfficerAug 25 '23Sale1.097,4428,10430,753Aug 25 04:45 PM
Palmer Pamela PChief Medical OfficerAug 24 '23Sale1.179,51411,13138,195Aug 25 04:45 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • careers • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.